Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

When even the most highly trained surgeons perform procedures on the retina-one of the smallest, most delicate parts of the human body-the stakes are high. Surgeons must account for patients' ...

ALPHARETTA, Ga., May 21, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Even with good control of the underlying uveitis through systemic immunomodulatory therapy, uveitic macular edema often ...

The EYLEA Injection delivers a high-dose anti-VEGF treatment for age-related macular degeneration and other retinal diseases in a compact 8 mg formulation. This bestseller drives the price of ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr Dao Nguyen examines a vial of lutein formulation developed for potential use in eyedrop treatments. (CREDIT: Will Wright, RMIT ...